A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention
|
|
- Maurice Fisher
- 6 years ago
- Views:
Transcription
1 A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research Foundation
2 Dissapointing results for non-nitinol nitinol stents Results of the first generation self-expanding expanding stents (WallStent & Strecker stent) in the SFA FU Lesion length Primary Patency Van Der Zaag et al EJVES 2004 Conroy et al J Vasc Int Radiol 2000 Gordon et al Arch Surg 2001 Cheng et al Ann Vasc Surg M 24M 12M 24M 5-15 cm 43% mean 13.5 cm 36% mean 14.5 cm 55% mean 16 cm 35% 1
3 TASC classifications of SFA lesions
4 Levels of evidence Source: US Preventive Services Task Force Level I Level IIa Level IIb Level IIc Level III well-designed, prospective, randomized, controlled trials well-designed, prospective, non-randomized, controlled trials well-designed, prospective, non-randomized, non-controlled cohort or case-control control analytic studies retrospective, non-randomized, non-controlled multiple time series expert opinions, based on clinical experience, descriptive studies or reports of expert committees 3
5 Summary of non-randomized trial results Levels IIa, IIb, IIc Reference stent lesion length prim patency name Jahnke 2002 IntraCoil % Wiesinger 2005 Covered SMART % Henry 1996 VascuCoil < 4 89 % Sabeti 2004 any 5 75 % Lugmayr 2002 Symphony < 6 87 % Lenti 2007 aspire unk 64 % Schillinger 2001 any % Fischer 2006 Hemobahn/Viabahn % Jahnke 2003 Hemobahn % Schlager 2005 any % Lammer 2000 Hemobahn % Cheng 2001 any % Daenens 2005 Hemobahn % Cheng 2003 any % Bray 2005 Hemobahn % Biamino 2002 SMART % 4
6 WL Gore Hemobahn vs. Study description: Single-center experience as part of a US prospective, randomized, controlled, multi-center study Balloon angioplasty vs. Hemobahn (Gore) eptfe-covered endoprosthesis placement Inclusion period: Jun 1998 Dec 1999 Saxon et al. J Vasc Interv Radiol 2003;14:
7 WL Gore Hemobahn vs. Randomization scheme 28 patients Randomization (n = 13) Hemobahn (n = 15) Saxon et al. J Vasc Interv Radiol 2003;14:
8 WL Gore Hemobahn vs. Lesion information Hemobahn Average lesion length 6.32cm ( ) 7.41cm ( ) TASC A 1 0 TASC B 8 5 TASC C 3 6 TASC D 1 4 Saxon et al. J Vasc Interv Radiol 2003;14:
9 WL Gore Hemobahn vs. 87% 23% Saxon et al. J Vasc Interv Radiol 2003;14:
10 WL Gore Hemobahn vs. Conclusions for medium length lesions Patency rates after Hemobahn implantation were significantly better than those after balloon angioplasty Clinical success rate was significantly higher in the Hemobahn group Saxon et al. J Vasc Interv Radiol 2003;14:
11 Absolute stent vs. Prospective, randomized, controlled, single-center Balloon angioplasty vs. nitinol stent implantation Inclusion period: Jun 2003 Aug 2004 Schillinger et al. NEJM 2006;354:
12 Absolute stent vs. Randomization scheme on treatment basis 104 patients Randomization (n = 53) Stent (n = 51) Crossover due to insufficient result (n = 17 [32%]) Schillinger et al. NEJM 2006;354:
13 Absolute stent vs. Randomization scheme on treatment basis 104 patients Randomization (n = 53) Stent (n = 51) Crossover due to insufficient result (n = 17 [32%]) (n = 36) on treatment Stent (n = 68) Schillinger et al. NEJM 2006;354:
14 Absolute stent vs. Lesion information Nitinol stent Average lesion length 9.2cm (±6.4)( 10.1cm (±7.5)( Occlusions 19% (±10)( 17% (±10)( Schillinger et al. NEJM 2006;354:
15 Absolute stent vs. intention to treat on treatment % p=0.05 (significant) 66 % % p=0.03 (significant) 75 % 10 0 (30/53) Stent (39/51) 10 0 (18/36) Stent (51/68) Schillinger et al. NEJM 2006;354:
16 Absolute stent vs. Based on intention to treat principle After 6 months After 12 months % p=0.01 (significant) % % 30 p=0.06 (not significant) % (29/53) Stent (38/51) 10 0 (19/52) Stent (31/49) Schillinger et al. NEJM 2006;354:
17 Absolute stent vs. Conclusion for medium length lesions Angiography showed significantly better restenosis enosis rates for the stent group at 6 months Duplex sonography confirmed significantly better restenosis rates at 12 months Clinical worsening was rare in either group Reintervention rates were similar in both groups Schillinger et al. NEJM 2006;354:
18 vs. Lumunexx Stent Prospective, randomized, controlled Balloon angioplasty vs. Luminexx nitinol stent Femoral Artery Stenting Trial SFA lesions between 1 and 10cm in length Only 1 stent per treated lesion Krankenberg H et al. Circulation 2007;116; ;
19 vs. Lumunexx Stent Randomization scheme on treatment basis 244 patients Randomization (n = 121) Stent (n = 123) Crossover due to insufficient result (n = 13 [11%]) Krankenberg H et al. Circulation 2007;116; ;
20 vs. Lumunexx Stent Randomization scheme on treatment basis 244 patients Randomization (n = 121) Stent (n = 123) Crossover due to insufficient result (n = 13 [11%]) (n = 108) on treatment Stent (n = 136) Krankenberg H et al. Circulation 2007;116; ;
21 vs. Lumunexx Stent Lesion information: short to medium length lesions Luminexx stent Average lesion length 44.5mm 45.2mm not signifcant Occlusions 25% 37% not signifcant Krankenberg H et al. Circulation 2007;116; ;
22 vs. Lumunexx Stent intention to treat on treatment % 68.3 % % 67 % p=0.377 (not significant) p=0.554 (not significant) (62/101) Stent (69/101) 10 0 (56/90) Stent (75/112) Krankenberg H et al. Circulation 2007;116; ;
23 vs. Lumunexx Stent Conclusion The Femoral Artery Stenting Trial failed to demonstrate the superiority of the Luminexx nitinol stent over stand-alone alone in the treatment of patients with superficial femoral artery (SFA) lesions 1-10cm 10cm in length Krankenberg. TCT 2006
24 SIROCCO I & II: SES vs. BMS Double-blind, blind, randomized, prospective (sirolimus( vs. bare stent) SIROlimus Coated Cordis SMART Nitinol Self-expanding expanding stent for the treatment of Obstuctive SFA disease Phase 1: 36 patients max 3 stents >70% stenosis >7cm to <20cm occlusion >4cm to <20cm Phase 2: 57 patients max 2 stents lesion length >7cm to <14.5cm occlusion >4cm to <14.5cm
25 SIROCCO I & II Baseline Lesion Characteristics Sirolimus (n=29) Control (n=28) P- value Thrombus (%) Moderate/Severe Calcification (%) Total Occlusion (%) Lesion Length (mm) 86.5 ± ± Reference Vessel Diameter (mm) 4.92 ± ± Pre Percent Diameter Stenosis (%) 95.8 ± ±
26 SIROCCO I & II Duplex 24-month Slower Eluting (n=5) Fast Eluting (n=11) Control (n=17) Binary Restenosis Rate %(n) 40.0 (2) 44.4 (4) 47.1 (8) Total Occlusion %(n) (1) Total Restenosis/Occlusions %(n) 40.0 (2) 44.4 (4) 52.9 (9) Target Lesion Revascularization %(n) (1) 5.8 (1)
27 SIROCCO I & II 24-month Pooled SR SIROCCO I-II (n=16) Control SIROCCO I-II (n=14) p value Minimum Lumen Diameter 2.15mm 2.15mm Stent Mean Diameter 3.42mm 3.35mm In-stent restenosis - unreadable - patent 3 (18.8%) 9 (56.3%) 2 (14.3%) 8 (57.1%) % and <70% 4 (25.0%) 2 (14.3%) - 70% and <100% - 1 (7.1%) - occlusion - 1 (7.1%)
28 SIROCCO I & II: conclusions Fractures associated with Multiple stents Longer stented lengths Frequently adjacent to the overlaps (not in the overlap areas themselves) No relationship between fracture and restenosis Sirolimus-eluting stents are safe for SFA treatment Excellent results with bare SMART stent In-stent binary restenosis rate : 24 months (angiographically) Duda et al. Cx
29 Zilver PTX: PES vs. BMS Randomized Study (480 pts) Phase 1: 60 patients lesions < 7 cm, up to 1 stent per limb enrollment complete Phase 2: 420 patients Lesions < 14 cm, up to 2 stents per limb Currently enrolling Registry Study (760 pts) Up to 4 Zilver PTX stents per patient Currently enrolling: more than 700 patients enrolled/approximately 2500 stents implanted
30 PTX: Baseline angiographic data Lesion Length (cm) Randomized Study (Phase 1) (N = 33 lesions) 3.6 ± 2.0 (range 1 to 7) ZPTX (N = 29 lesions) 4.1± 3.1 (range 1 to 10) Registry Study ZPTX (N = 91 lesions) 10 ± 8.1 (range 1 to 33) Proximal RVD (mm) 5.2 ± ± ± 0.8 Distal RVD (mm) 5.3 ± ± ± 0.8 MLD in lesion (mm) 1.3 ± ± ± 0.7 % Diameter Stenosis 76 ± ± ± 12
31 Zilver PTX: 6-month 6 effectiveness Study Freedom from TLR Phase 1 of the randomized study 52% [17/33] No failure 100% [17/17] acute failure BMS Zilver 75% [6/8] acute failure PTX Zilver 100% [8/8] 48%[16/33] Zilver PTX 90% [26/29] Registry Zilver PTX 90% [82/91]
32 RESILIENT: LifeStent vs. n=20 + LifeStent Phase I: 6 sites Only Control Arm n=69 n=20 roll-in + LifeStent n=206 randomly allocated 1 : 2 Phase II: 24 sites + LifeStent Test Arm n=137 Biamino G, Katzen BT, Laird J. The RESILIENT Trial: 12-mos. results. Leipzig Interventional Course. Leipzig, Germany, 2008.
33 RESILIENT: Bail-out lesion characteristics Lesion Length/patient (mm) 52.0 ± ± 44.3 p= p= ± 37.8 * = Visual Estimate + = t-test for Equality of Means Biamino G, Katzen BT, Laird J. The RESILIENT Trial: 12-mos. results. Leipzig Interventional Course. Leipzig, Germany, 2008.
34 RESILIENT Results:12-Month 100% 80% 86% 86% *Data from Kaplan-Meier Survival Analysis 80% 87% +LifeStent 72% 60% 40% p=.91 38% 46% 34% 20% p<.0001 p<.0001 p< % Freedom from MACE* Prim. Patency (duplex)* Freedom from TLR* Clinical success Biamino G, Katzen BT, Laird J. The RESILIENT Trial: 12-mos. results. Leipzig Interventional Course. Leipzig, Germany, 2008.
35 RESILIENT: behind the numbers Bail-out stenting (crossover) in the group occurred 40.2% (29/72) for: Major flow-limiting limiting dissection (38%) Residual stenosis >30% (62%) Confirmed as acceptable by Core Lab and CEC Procedural crossover to stenting in the group was defined as a TLR and counted as a primary endpoint and patency failure Biamino G, Katzen BT, Laird J. The RESILIENT Trial: 12-mos. results. Leipzig Interventional Course. Leipzig, Germany, 2008.
36 Clinical trial comparison using the reported rates of TLR STENT STENT ABSOLUTE VIENNA (12 mos., 10.1 cm) RESILIENT (12 mos., 7.1 cm) ZILVER PTX (6 mos., 4.1 cm)
37 Clinical trial comparison using the RESILIENT/ZILVER PTX definitions of TLR STENT STENT ABSOLUTE VIENNA (12 mos., 10.1 cm) RESILIENT (12 mos., 7.1 cm) ZILVER PTX (6 mos., 4.1 cm)
38 Clinical trial comparison using the ABSOLUTE/VIENNA definitions of TLR STENT STENT ABSOLUTE VIENNA (12 mos., 10.1 cm) RESILIENT (12 mos., 7.1 cm) ZILVER PTX (6 mos. 4.1 cm)
39 SFA Challenges: Data collection Data collection Endpoint definitions of success Anatomic Binary restenosis (>50%) Discrete vs. diffuse vs. volume definitions Clinical Walking distance ABI Quantifying (and understanding) restenosis Angiographic Duplex Intravascular ultrasound Time course defining durability of intervention Consistent and standardized reporting structure
40 Patient factors with unclear influence on interventional outcomes Inflow/Run-off off status Length of disease Vessel diameter Occlusion vs. stenosis Diabetic status Tobacco status Atheroma volume Calcification Gender
41 Procedural factors with unclear influence on interventional outcomes Stents Number Degree of overlap Compression or stretch during implant Significant oversizing or undersizing Adjunctive debulking
42 SFA: Design challenges This arterial territory response to intervention is poorly understood There are no large-scale data sets from which to establish design goals Such data was critical to the understanding of coronary stent behavior and the opportunity to improve the technology in a focused direction
43 Multi-Link Penta*, , 0.90mm Late Loss in Bare Metal Stents 6-mo Follow-Up ASCENT VISION PENTA REGISTRY DISTINCT NIRVANA VENUS VELVET 1 RAVEL Ctrl Bx VELOCITY,.0055, 0.80mm Multi-Link Vision*,.0032, 0.83mm NIR*,.0040", 0.80mm Bx VELOCITY,.0055, 0.97mm Bx VELOCITY,.0055, 0.70mm Multi-Link,.0022", 0.90mm QCA Late Loss (mm) BiodivYsio TM *,.0036, 0.80mm
44
45 Result of lack of outcome data Current efforts at designing successful devices which will have improved outcomes are at best estimates of the causal relationships In the typically small clinical trials testing in SFA therapies, these devices are subject to variation in subject/vessel characteristics
46 Conclusions Stents are better than (I think) for limited lesion length Long stents are worse than short stents Not all stent fractures are created equal FESTO results not borne out in later trials Alternative therapies (photodynamic, adventitial injection, adjunctive atherectomy,, etc.,) may be useful but as yet untested Drug-eluting balloon looks interesting in spite of lack of clear mechanism VIBRANT trial data will be interesting
Update in femoral angioplasty & stenting PRO
MEET 2008 Update in femoral angioplasty & stenting Will extra-long stents be a solution for SFA disease? PRO Patrick Peeters, MD Chief department Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden,
More informationThe Final Triumph Of Endovascular Therapy In SFA Treatment
The Final Triumph Of Endovascular Therapy In SFA Treatment MEET 07 Mark W. Mewissen, M.D. Director, St Lukes Vascular Center Milwaukee, WI Endovascular Therapy In SFA Treatment: Works In Progress! Mark
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationDisclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA
In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA Disclosures No financial disclosures. Cameron M. Akbari, MD, MBA, FACS Site Director, Vascular Surgery Medstar
More informationMEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?
MEET 2009 SFA stenting in 2009 : The good and the ugly What factors influence patency? M. Bosiers K. Deloose P. Peeters 1 TASC II 2007 vs TASC 2000 Type A Type B Type C Type D 2000 < 3 cm 3-5 cm < 3 cm
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More information4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters
Drug-eluting technology in the SFA and Popliteal David Paul Slovut, MD, PhD Associate Professor of Medicine and Surgery Co-director of TAVR program Director of Advanced Intervention Faculty Disclosure
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationAtherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System
Atherectomy is Still Live and Effective John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System Why is Atherectomy Still Alive? Improved devices Better data
More informationRobert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationNew Data to Shape the Era of Drug Elution in Peripheral Interventions
New Data to Shape the Era of Drug Elution in Peripheral Interventions William A. Gray MD Director of Endovascular Services Columbia University Medical Center New York Lower Extremity Endovascular - Interventions
More informationMerits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁
Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁 Contents DES in SFA DES in BTK DEB in SFA DEB in BTK Current status of covered stent
More informationUtility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography
Utility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography Jon C. George, MD; Vincent Varghese, DO From the Deborah Heart and Lung Center, Browns Mills, New Jersey. ABSTRACT:
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationOn behalf of the DURABILITY Investigators:
On behalf of the DURABILITY Investigators: S. Müller-Hülsbeck 1, M. Bosiers 2, G. Torsello 3, D. Scheinert 4, H. Gissler 5, J. Ruef 6, T. Jahnke 7, P. Peeters 8, K. Daenens 9, J. Lammer 1 1 Ev.-Luth. Diakonissenanstalt
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationAccurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery
Accurate Vessel Sizing Drives Clinical Results IVUS In the Periphery Discussion Iida O, et. al. Study Efficacy of Intravascular Ultrasound in Femoropopliteal Stenting for Peripheral Artery Disease With
More informationLatest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationTools and options for recanalisation of long-femoro-popliteal segments
Tools and options for recanalisation of long-femoro-popliteal segments Pr E Ducasse Unit of Vascular Surgery University of Bordeaux ESVB 2011-may 14th E Ducasse, G Sassoust, D Midy THE ACCESS!! Retrograde
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA Why atherectomy? Calcification is the norm not the exception Most trials do not include heavy calcification There
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationDrug Elution, Data, and Decisions
Drug Elution, Data, and Decisions What the data tell us about how to integrate drug-eluting technology into our daily practice. BY GARY ANSEL, MD, AND JOHN A. PHILLIPS, MD The use of drug-eluting technology
More informationBioMimics 3D in my Clinical Practice
BioMimics 3D in my Clinical Practice M Lichtenberg M.D. Vascular Centre Arnsberg / German Venous Centre Arnsberg CAUTION: Investigational Device. Limited by Federal (or United States) Law to Investigational
More informationTreatment Strategies for Long Lesions of greater than 20 cm
Treatment Strategies for Long Lesions of greater than 20 cm Donald L. Jacobs, MD C. Rollins Hanlon Professor and Chair Chair of the Department of Surgery Saint Louis University Disclosure Speaker name:
More informationBrachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts
Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts Disclosure Speaker name: Matthew T. Menard... x I do not have
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More informationSustained Release. Superior Results.
ELUVIA Drug-Eluting Vascular Stent System Sustained Release. Superior Results. Superiority determined in Post Hoc Superiority Analysis. 12-Month Primary Patency rate of 86.8% in the Eluvia arm (n=309)
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationSFA In-stent Restenosis
Disclosure In-Stent Restenosis: Endo-Salvage Works for Most Patients Peter A. Schneider, MD Hawaii Permanente Medical Group and Kaiser Foundation Hospital Honolulu, Hawaii Peter A. Schneider Potential
More informationShockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany
Shockwave Medical Lithoplasty Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany Disclosure Speaker name: Thomas Zeller, MD I have the following potential conflicts of interest
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationUpdate on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany
Update on the Levant 2 Clinical Trial Programme Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have the following potential conflicts of interest
More informationDisclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?
Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long? UCSF Vascular Symposium 2017 April 6-8, 2017 San Francisco, CA Disclosures Consulting, Speakers
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
More informationStents for Femoropopliteal Disease:
1 TheZilverPTX RandomizedTrial ofpaclitaxel Eluting Stents for Femoropopliteal Disease: 24 Month thupdate Mark kw. Burket, MD M.D. Professor of Medicine Director of Vascular Medicine University of Toledo
More informationBIOFLEX PEACE Registry
BIOFLEX PEACE Registry Pulsar Efficacy: an All Comers Registry INTERIM ANALYSIS Michael K. W. Lichtenberg On behalf of the BIOFLEX-PEACE study group Definition and understanding of various radial forces
More informationWhen Outcomes Matter, Design Matters
to receive our latest news and key activities. Cordis S.M.A.R.T. Self-Expanding Nitinol Lower Extremity Solutions When Outcomes Matter, Design Matters For superficial femoral artery (SFA) and iliac lesions.
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationUpdate on the Ranger clinical trial programme
Update on the Ranger clinical trial programme Dierk Scheinert, MD Universitätsklinikum Leipzig, Leipzig, Germany on behalf of the RANGER SFA investigators Disclosure Speaker s name: Dierk Scheinert I have
More informationDisclosures: Stent-grafts for Long-Segment SFA Disease: Better than the Alternatives? SFA Treatment Overview: Longer Lesions 4/18/2013
Stent-grafts for Long-Segment SFA Disease: Better than the Alternatives? Richard Saxon MD Director of Research San Diego Cardiac and Vascular Institute San Diego Imaging Medical Group San Diego, CA Disclosures:
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationTOBA Trial 12 months Results
Tack Optimized Balloon Angioplasty: TOBA Trial 12 months Results New Paradigm for Managing Post PTA Dissections Marc Bosiers, MD A.Z. St. Blasius Hospital, Belgium Disclosure Speaker name: Dr. Marc Bosiers
More informationDrug- Coated Balloons for the SFA: Overview of Technology and Results
Drug- Coated Balloons for the SFA: Overview of Technology and Results NCVH Latin American 2015 Bogota, Colombia April 9-11, 2015 Brian G. DeRubertis, M.D. Associate Professor of Surgery Division of Vascular
More informationAngiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-
Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis- Masahiko Fujihara Kishiwada Tokushukai Hospital, Osaka, Japan Disclosure
More informationMassimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany
Intravascular Stenting and Angiographic Results: Randomized Comparison of STenting, Stenting after Paclitaxel-eluting balloon and ATHerectomy in patients with symptomatic Peripheral Artery Disease - Results
More informationOr is the ivolution stent a better alternative? EVOLUTION 12-month data
Or is the ivolution stent a better alternative? EVOLUTION 12-month data Dr. Marc Bosiers LINC 2018, Leipzig Conflict of interest have the following potential conflicts of interest to report: Consulting
More informationDCB level 1 evidence review
DCB level 1 evidence review Raphaël COSCAS Vascular Surgery Department Ambroise Paré Hospital, AP-HP and Paris-Ouest University Boulogne-Billancourt, France Disclosure Speaker name: Raphael COSCAS I have
More informationTurbo-Power. Laser atherectomy catheter. The standard. for ISR
Turbo-Power Laser atherectomy catheter The standard for ISR Vaporize the ISR challenge In-stent restenosis (ISR) Chance of recurring 7 115,000 + /year (U.S.) 1-6 Repeated narrowing of the arteries after
More informationClinically proven. ordering info. Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW. Pulsar-18
140 μm thin struts Clinically proven 4F low profile Vascular Intervention // Peripheral Self-Expanding Stent System/0.018 /OTW Pulsar-18 Technical data / ordering info 140 μm thin struts - thinner than
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More informationMaking BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationEvolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data
Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden Hospital Charité, CC11 Academic Teaching Hospitals
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationMinimizing Burden, the effect of thin strut and low Chronic Outward Force SE stents
Minimizing Burden, the effect of thin strut and low Chronic Outward Force SE stents Prof. Yong LIU The affiliated hospital of southwest medical university LINC AP 2018, Hong Kong 13-15 th March Disclosure
More informationSpecificities for infrapopliteal stents
Specificities for infrapopliteal stents Nicolas Diehm, M.D. Swiss Cardiovascular Center Clinical and Interventional Angiology University Hospital Bern, Switzerland Disclosures Speaker`s Bureau: MEDRAD,
More informationSuperficial Femoral Artery Intervention: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA
: The gift that keeps on giving! Wm. Britton Eaves,MD WKHSC Bossier City, LA Peripheral arterial disease (PAD) of the superficial femoral artery (SFA) is the most common cause of intermittent claudication
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationESVB State of the art: DES, DCB and the role of debulking. Gunnar Tepe, Rosenheim
ESVB 2013 State of the art: DES, DCB and the role of debulking Gunnar Tepe, Rosenheim DES I Sirocco Sirolimus coating, quick release Duda et al., J Vasc Surg 2002; 106: 1505-1509 20 DES II Strides Everolimus
More informationUpdate on the role of drug eluting balloons
Update on the role of drug eluting balloons William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research
More informationDISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.
DISRUPT PAD (( Data Summary )) DISRUPT PAD Data Summary SPL 60971 Rev. B 1 Summary of the key findings from the DISRUPT PAD Study 99% of femoropopliteal lesions treated were moderately or severely calcified.
More informationThe BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA
The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA BATTLE RCT investigators: Y. Gouëffic, A. Sauguet, P. Desgranges, P. Feugier, E. Rosset, E. Ducasse,
More informationSFA lesion treatment: China experience. Wei Liang, MD
SFA lesion treatment: China experience Wei Liang, MD Disclosure I do not have any potential conflict of interest Background PAD: 14% - 20% in adults Aorta & Iliac A: 30% Femoral & Pop A: 80-90% Tibial
More informationREACT Treatment Rationale and Clinical Evidence. ICI Meeting 5th of December 2017
REACT Treatment Rationale and Clinical Evidence ICI Meeting 5th of December 2017 The SFA is a challenging vessel to treat Shortening 23-25%1 Compression > 1kg2 Torsion 60 3 Bending 64 4 SFA, superficial
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationDisclosures. Carotid artery stenting. Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence
Disclosures Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of
More informationLong-term results with interwoven nitinol stents vs. BMS vs. DCB
Long-term results with interwoven nitinol stents vs. BMS vs. DCB Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant: Abbott,
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationLessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?
Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention? Michael Wholey, MD, MBA San Antonio, TX USA 19/06/2009 at 09:35 during 4mn as a Speaker Session: Improving Femoral Artery Recanalization
More informationEndovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial
Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial Prof. Thomas Zeller, MD Department Angiology Clinic for Cardiology and Angiology II University Heart-Center
More informationNicolas W Shammas, MD, MS
Rota%onal and Aspira%on Atherectomy in Trea%ng in- Stent Restenosis of Femoropopliteal Arteries: Final Results of the JETSTREAM- ISR Feasibility Study Nicolas W Shammas, MD, MS President and Research Director,
More informationDisclosures. In-Stent Restenosis: The Tail IS Wagging the Dog 4/15/2016. Restenosis: The Continuing Challenge for Peripheral Vascular Intervention
In-Stent Restenosis: The Tail IS Wagging the Dog Disclosures NONE Michael S. Conte MD Division of Vascular and Endovascular Surgery UCSF Heart and Vascular Center UCSF Vascular Symposium 2016 IF YOU WERE
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationTreating In-Stent Restenosis with Brachytherapy: Does it Actually Work?
Treating In-Stent Restenosis with Brachytherapy: Does it Actually Work? Matthew T. Menard, M.D. Brigham and Women s Hospital Pacific Northwest Endovascular Conference June 15, 2018 DISCLOSURE Matthew Menard,
More informationRELINE-trial : 24 months results with the Viabahn vs PTA for in-stent restenosis
LINC 2015, Leipzig A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist OLV Hospital, Aalst RELINE-trial : 24 months results
More informationLate Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance
Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Richard Kuntz Brigham and Women s s Hospital Harvard Medical School Late Loss and DES Brief history of Late Loss
More informationOCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD
OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter Patrick Muck, MD Chief, Division of Vascular Surgery Good Samaritan Hospital Cincinna
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationCHALLENGES IN FEMORO-POPLITEAL STENTING
CHALLENGES IN FEMORO-POPLITEAL STENTING Karathanos C MD, MSc, PhD, Athanasoulas A, Rousas N, Spanos K, Giannoukas A Department of Vascular Surgery, University Hospital of Larissa, Faculty of Medicine,
More informationDierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
More informationEvidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
More informationIVUS Guided Case Review Case Performed by Frank R. Arko III, MD Charlotte, NC
IVUS Guided Case Review Case Performed by Frank R. Arko III, MD Charlotte, NC The opinions and clinical experiences presented herein are for informational purposes only. Dr. Arko is a paid consultant for
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationVascular Medicine. Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional Stenting
Vascular Medicine Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional Stenting Martin Schillinger, MD; Schila Sabeti, MD; Petra Dick, MD; Jasmin
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More information